Last update April 2, 2024

Triamcinolone (topical use)

Compatible

Safe product and/or breastfeeding is the best option.

Corticosteroid with main glucocorticoid action and moderate anti-inflammatory effect (ATC D07AB), slightly superior to prednisolone. Indicated for topical dermatological use in the treatment of various dermatitis. 

This comment is about TOPICAL use Triamcinolone; for systemic, intra-articular, ophthalmic and inhaled use, see Inhaled Triamcinolone, Systemic Triamcinolone. TOPICAL USE:

Poor absorption through skin and even mucous membranes (Ramadas 2016, Meynadier 1981, Rasmussen 1978) makes passage of significant amount into breast milk unlikely. 

If required to treat eczema or nipple dermatosis, choose the least potent corticosteroid, apply just after feeding so that it is reabsorbed before the next feeding; carefully wipe off with gauze before breastfeeding. (Deleuran 2024, Vestergaard 2019)

Do not use for more than one week in a row. Mineralcorticoid intoxication has occurred in an infant by continuous application of a corticosteroid to the nipple. (De Stefano 1983)

Avoid application of creams, gels and other topical products containing kerosene (mineral oil) on the nipple so that they are not absorbed by the infant. (Concin 2008, Noti 2003)


See below the information of these related products:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Triamcinolone (topical use) in other languages or writings:

Group

Triamcinolone (topical use) belongs to this group or family:

Tradenames

Main tradenames from several countries containing Triamcinolone (topical use) in its composition:

List of 11 tradenames
  • Aldoderma™. Contains other elements than Triamcinolone (topical use) in its composition
  • Anso™. Contains other elements than Triamcinolone (topical use) in its composition
  • Aristocort™
  • Aureocort™. Contains other elements than Triamcinolone (topical use) in its composition
  • Azucort™
  • Glytop™
  • Ledermix™. Contains other elements than Triamcinolone (topical use) in its composition
  • Pevison™. Contains other elements than Triamcinolone (topical use) in its composition
  • Pevisone™. Contains other elements than Triamcinolone (topical use) in its composition
  • Positon™. Contains other elements than Triamcinolone (topical use) in its composition
  • Sorsis™. Contains other elements than Triamcinolone (topical use) in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Baja - Poor (dermat) %
Molecular weight 394 daltons
Protein Binding 68 %
VD 1.4 l/Kg
pKa 13.4 -
T½ 2 hours

References

  1. Deleuran M, Dézfoulian B, Elberling J, Knutar I, Lapeere H, Lossius AH, Schuttelaar MLA, Stockman A, Wikström E, Bradley M, de Bruin-Weller M, Gutermuth J, Mandelin JM, Schmidt MC, Thyssen JP, Vestergaard C. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):31-41. Abstract Full text (link to original source)
  2. Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P, Flohr C, Trzeciak M, von Kobyletzki L, Seneschal J, Paul C, Bieber T, Werfel T, Fölster-Holst R, Darsow U, Gieler U, Svensson Å, Cork M, Stalder JF, De Raeve L, Kunz B, Simon D, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1644-1659. Abstract Full text (link to original source)
  3. Ramadas AA, Jose R, Arathy SL, Kurup S, Chandy ML, Kumar SP. Systemic absorption of 0.1% triamcinolone acetonide as topical application in management of oral lichen planus. Indian J Dent Res. 2016 Abstract
  4. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  5. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract
  6. De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helv Paediatr Acta. 1983 Abstract
  7. Meynadier J, Guilhou JJ, Peyron JL. [Percutaneous absorption of triamcinolone 16 alpha, 17 alpha cyclopentylene-dioxy-21-acetate (author's transl)]. Dermatologica. 1981 Abstract
  8. Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol. 1978 Abstract

Total visits

33,266

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM